Time for integrating clinical, lifestyle and molecular data to predict drug responses:Authors' reply by Pottegård, Anton et al.
Syddansk Universitet
Time for integrating clinical, lifestyle and molecular data to predict drug responses
Authors' reply
Pottegård, A; Friis, Søren; Christensen, René dePont; Habel, Laurel A; Gagne, Joshua J;
Hallas, Jesper
Published in:
EBioMedicine
DOI:
10.1016/j.ebiom.2016.03.019
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY-NC-ND
Citation for pulished version (APA):
Pottegård, A., Friis, S., Christensen, R. D., Habel, L. A., Gagne, J. J., & Hallas, J. (2016). Time for integrating
clinical, lifestyle and molecular data to predict drug responses: Authors' reply. EBioMedicine, 7, 11. DOI:
10.1016/j.ebiom.2016.03.019
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
EBioMedicine 7 (2016) 11
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comCommentaryTime for integrating clinical, lifestyle and molecular data to predict drug
responses — Authors' replyAnton Pottegård a,⁎, Søren Friis b, René dePont Christensen a, Laurel A. Habel c, Joshua J. Gagne d, Jesper Hallas a
a Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark
b Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen Ø, Denmark
c Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA
d Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USADOIs of original article: http://dx.doi.org/10.1016
dx.doi.org/10.1016/j.ebiom.2016.03.031.
⁎ Corresponding author at: Clinical Pharmacology, Univ
Winsløwsvej 19, 2, DK-5000 Odense C, Denmark.
E-mail address: apottegaard@health.sdu.dk (A. Potteg
http://dx.doi.org/10.1016/j.ebiom.2016.03.019
2352-3964/© 2016 The Authors. Published by Elsevier B.Va r t i c l e i n f oArticle history:
Received 11 March 2016
Accepted 11 March 2016
Available online 18 March 2016
is only available for a subset of the study population, e.g. survey
data of life-style factors. Another example is recursive partitioning
(Seeger et al., 2006), which can be used to reﬁne study variables
(e.g., confounders or outcomes) in a subset of the population that can
then be applied to the entire study population.Thank you for an excellent and comprehensive commentary
(Patrignani and Dovizio, 2016) that highlights the ﬁndings of our
paper (Pottegård et al., 2016) and provides suggestions for the road
forward in pharmacoepidemiologic studies. While “individualized ther-
apy” is somewhat beyond the scope of the current study, utilizing an
epidemiological/population-based analysis, we fully agree that research
integrating clinical, lifestyle, and molecular data is an important step
forward for improving drug therapy. In our opinion, our approach
targeting multiple drug-cancer associations and the applied analyses
can be considered a ﬁrst step towards such integrated studies. However,
the challenge lies in identifying data sources that can provide drug,
clinical, lifestyle and genetic data for a sufﬁciently large population. In
the context of the present study (Pottegård et al., 2016), we used pre-
scription drug data dating back to 1995 (Kildemoes et al., 2011). Long-
term data are necessary in the study of outcomes with long latency
such as cancer (Umar et al., 2012). Importantly, the casemight be differ-
ent for acute events, such as bleeding or cardiovascular events. We
believe that advances in the study of cancer risk associated with
prescription drug use will require innovative methods that make use
of detailed data on a subset of a population in ways that leverage the in-
formation for the analysis of the full population. One example in
pharmacoepidemiology is propensity score calibration (Stürmer et al.,/j.ebiom.2016.03.018, http://
ersity of Southern Denmark, JB
ård).
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